drugset / Trial / NCT02876900

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

NCT02876900

Phase 3 Completed 617 enrolled Noven Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.

Timeline

Start
2016-08
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Asenapine Other / unclassified 3.8 mg Other
Subject Asenapine Other / unclassified 7.6 mg Other

Indications